Savara Inc (SVRA)

Dec 31, 2025

Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN

Dec 31, 2025

Dec 31, 2025

FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo

Dec 31, 2025

Dec 30, 2025

Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat

Dec 30, 2025

Dec 30, 2025

Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat

Dec 30, 2025

Dec 29, 2025

Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn

Dec 29, 2025

Dec 28, 2025

Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo

Dec 28, 2025

Dec 28, 2025

With 37% Ownership in Savara Inc. (NASDAQ:SVRA), Institutional Investors Have a Lot Riding on the Business - 富途牛牛

Dec 28, 2025

Dec 28, 2025

Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA - MarketBeat

Dec 28, 2025

Dec 28, 2025

Gap Down: Is Savara Inc YB4P stock a buy for dividend portfolios2025 Trade Ideas & AI Based Buy and Sell Signals - moha.gov.vn

Dec 28, 2025

Dec 28, 2025

How Savara Inc. stock reacts to Fed rate cutsSector Performance Review & Your Free Entry to Smart Investing Starts Here - bollywoodhelpline.com

Dec 28, 2025

Dec 26, 2025

Savara price target raised to $10 from $8 at HC Wainwright - MSN

Dec 26, 2025

Dec 26, 2025

Savara Inc. ticks higher amid takeover speculation - MSN

Dec 26, 2025

Dec 25, 2025

Market Review: How MTEN stock performs in high volatility marketsMarket Trend Report & Accurate Intraday Trade Tips - moha.gov.vn

Dec 25, 2025

Dec 25, 2025

What is HC Wainwright's Forecast for Savara FY2027 Earnings? - MarketBeat

Dec 25, 2025

Dec 24, 2025

Savara (SVRA) Stock Price, Quote, News & History - Benzinga

Dec 24, 2025

Dec 24, 2025

FY2029 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat

Dec 24, 2025

Dec 24, 2025

SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Dec 24, 2025

Dec 23, 2025

Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission By Investing.com - Investing.com South Africa

Dec 23, 2025

Dec 23, 2025

Savara (SVRA) Receives Revised Buy Rating from HC Wainwright & C - GuruFocus

Dec 23, 2025

Dec 23, 2025

Savara stock price target raised to $10 from $8 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Dec 23, 2025

Dec 23, 2025

Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission - Investing.com Nigeria

Dec 23, 2025

Dec 23, 2025

Savara stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com Nigeria

Dec 23, 2025

Dec 23, 2025

How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st

Dec 23, 2025

Dec 22, 2025

Savara resubmits BLA for rare lung disease treatment with new manufacturer - Investing.com Nigeria

Dec 22, 2025

Dec 22, 2025

Savara (SVRA) Resubmits Molbreevi BLA to FDA for Autoimmune PAP Treatment - GuruFocus

Dec 22, 2025

Dec 22, 2025

Savara Resubmits Molbreevi Application to FDA for Rare Lung Disease - marketscreener.com

Dec 22, 2025

Dec 22, 2025

Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN

Dec 22, 2025

Dec 22, 2025

Savara resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi - marketscreener.com

Dec 22, 2025

Dec 22, 2025

Savara resubmits BLA for rare lung disease treatment with new manufacturer By Investing.com - Investing.com South Africa

Dec 22, 2025

Dec 22, 2025

Savara : Corporate Presentation - marketscreener.com

Dec 22, 2025

Dec 22, 2025

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance

Dec 22, 2025

Dec 21, 2025

Savara Inc.(NasdaqGS: SVRA) added to S&P Biotechnology Select Industry Index - marketscreener.com

Dec 21, 2025

Dec 21, 2025

Savara Locks In Long-Term Europe Protection for Rare Lung Drug MOLBREEVI - MyChesCo

Dec 21, 2025

Dec 21, 2025

Why Savara Inc. stock could rally in 2025Market Volume Summary & Daily Technical Forecast Reports - Улправда

Dec 21, 2025

Dec 20, 2025

How big funds are accumulating Savara Inc. (YB4P) stockOil Prices & Safe Capital Growth Stock Tips - Улправда

Dec 20, 2025

Dec 20, 2025

Why Savara Inc. (YB4P) stock could outperform next yearJuly 2025 Institutional & Entry Point Confirmation Signals - Улправда

Dec 20, 2025

Dec 19, 2025

Aug Closing: Why Savara Inc. stock could rally in 2025Profit Target & Safe Capital Allocation Plans - Улправда

Dec 19, 2025

Dec 19, 2025

Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail

Dec 19, 2025

Dec 19, 2025

Will Savara Inc. stock outperform tech sector in 2025Earnings Risk Summary & Real-Time Volume Trigger Notifications - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Can Savara Inc. stock beat market expectations this quarterJuly 2025 Price Swings & AI Driven Price Forecasts - DonanımHaber

Dec 19, 2025

Dec 19, 2025

How Savara Inc. stock benefits from global expansionGlobal Markets & Growth Focused Entry Point Reports - DonanımHaber

Dec 19, 2025

Dec 19, 2025

How Savara Inc. stock performs in weak economyJuly 2025 Decliners & Real-Time Volume Analysis Alerts - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Will Savara Inc. stock benefit from sector rotation2025 Dividend Review & Technical Entry and Exit Tips - Улправда

Dec 18, 2025

Dec 18, 2025

Wells Fargo Raises Price Target for Savara (SVRA) to $9.00 | SVR - GuruFocus

Dec 18, 2025

Dec 18, 2025

Savara (NASDAQ:SVRA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat

Dec 18, 2025

Dec 18, 2025

Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences - MSN

Dec 18, 2025

Dec 18, 2025

Breakouts Watch: Will Savara Inc. stock benefit from sector rotationJuly 2025 Volume & Weekly High Return Stock Forecasts - Улправда

Dec 18, 2025